» Articles » PMID: 36831688

Variation in Post-Transplant Cancer Incidence Among Italian Kidney Transplant Recipients over a 25-Year Period

Abstract

This cohort study examined 25-year variations in cancer incidence among 11,418 Italian recipients of kidney transplantation (KT) from 17 Italian centers. Cancer incidence was examined over three periods (1997-2004; 2005-2012; and 2013-2021) by internal (Incidence rate ratio-IRR) and external (standardized incidence ratios-SIR) comparisons. Poisson regression was used to assess trends. Overall, 1646 post-transplant cancers were diagnosed, with incidence rates/1000 person-years ranging from 15.5 in 1997-2004 to 21.0 in 2013-2021. Adjusted IRRs showed a significant reduction in incidence rates across periods for all cancers combined after exclusion of nonmelanoma skin cancers (IRR = 0.90, 95% confidence interval-CI: 0.76-1.07 in 2005-2012; IRR = 0.72, 95% CI: 0.60-0.87 in 2013-2021 vs. 1997-2004; P < 0.01). In site-specific analyses, however, significant changes in incidence rates were observed only for Kaposi's sarcoma (KS; IRR = 0.37, 95% CI: 0.24-0.57 in 2005-2012; IRR = 0.09, 95% CI: 0.04-0.18 in 2013-2021; P < 0.01). As compared to the general population, the overall post-transplant cancer risk in KT recipients was elevated, with a decreasing magnitude over time (SIR = 2.54, 95% CI: 2.26-2.85 in 1997-2004; SIR = 1.99, 95% CI: 1.83-2.16 in 2013-2021; P < 0.01). A decline in SIRs was observed specifically for non-Hodgkin lymphoma and KS, though only the KS trend retained statistical significance after adjustment. In conclusion, apart from KS, no changes in the incidence of other cancers over time were observed among Italian KT recipients.

Citing Articles

Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center.

Re Sarto G, Alfieri C, Cosmai L, Brigati E, Campise M, Regalia A Transpl Int. 2024; 37:13220.

PMID: 39228659 PMC: 11368674. DOI: 10.3389/ti.2024.13220.


Report on post-transplantation cancer in southeast Asia from the Thai kidney transplantation cohort.

Laowalert S, Naitook N, Boonnim K, Prungrit U, Aekkachaipitak N, Lamjantuek P Sci Rep. 2024; 14(1):20154.

PMID: 39215076 PMC: 11364626. DOI: 10.1038/s41598-024-71041-x.


Case report: Liver PEComa after kidney transplantation in recipient with tuberous sclerosis complex.

Dymkowski M, Kalman P, Niecikowski P, Koperski L, Kosieradzki M Front Oncol. 2024; 14:1386569.

PMID: 39026968 PMC: 11254673. DOI: 10.3389/fonc.2024.1386569.


Adverse Drug Events after Kidney Transplantation.

Rostaing L, Jouve T, Terrec F, Malvezzi P, Noble J J Pers Med. 2023; 13(12).

PMID: 38138933 PMC: 10744736. DOI: 10.3390/jpm13121706.

References
1.
Breslow N, Day N . Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987; (82):1-406. View

2.
Al-Adra D, Al-Qaoud T, Fowler K, Wong G . Malignancies after Kidney Transplantation. Clin J Am Soc Nephrol. 2021; 17(3):434-443. PMC: 8975024. DOI: 10.2215/CJN.14570920. View

3.
Huang B, Huang M, Zhang C, Yu Z, Hou Y, Miao Y . Individual dynamic prediction and prognostic analysis for long-term allograft survival after kidney transplantation. BMC Nephrol. 2022; 23(1):359. PMC: 9641958. DOI: 10.1186/s12882-022-02996-0. View

4.
Taborelli M, Serraino D, Cimaglia C, Furian L, Biancone L, Busnach G . The impact of cancer on the risk of death with a functioning graft of Italian kidney transplant recipients. Am J Transplant. 2021; 22(2):588-598. DOI: 10.1111/ajt.16825. View

5.
Turshudzhyan A . Post-renal transplant malignancies: Opportunities for prevention and early screening. Cancer Treat Res Commun. 2020; 26:100283. DOI: 10.1016/j.ctarc.2020.100283. View